Treatment of Atrial Fibrillation
January 8, 2024 (Issue: 1693)
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association...more
- JA Joglar et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2023 November 30 (epub). doi:10.1161/cir.0000000000001193
- MK Chung et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation 2020; 141:e750. doi:10.1161/cir.0000000000000748
- R Cardoso et al. Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis. Am J Med 2022; 135:228. doi:10.1016/j.amjmed.2021.08.026
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- SJ Connolly et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139. doi:10.1056/nejmoa0905561
- MR Patel et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883. doi:10.1056/nejmoa1009638
- CB Granger et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981. doi:10.1056/nejmoa1107039
- RP Giugliano et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093. doi:10.1056/nejmoa1310907
- WCY Lau et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. Ann Intern Med 2022; 175:1515. doi:10.7326/m22-0511
- MR Southworth et al. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272. doi:10.1056/nejmp1302834
- FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: https://bit.ly/3Nom3z7. Accessed December 18, 2023.
- Idarucizumab (Praxbind) – an antidote for dabigatran. Med Lett Drugs Ther 2015; 57:157.
- Andexxa – an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther 2018; 60:99.
- M Crowther et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2014; 124:4269. doi:10.1182/blood.V124.21.4269.4269
- SJ Connolly et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326. doi:10.1056/nejmoa1814051
- RD Lopes et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380:1509. doi:10.1056/nejmoa1817083
- DJ Angiolillo et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update. Circulation 2021; 143:583. doi:10.1161/circulationaha.120.050438
- S Yasuda et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019; 381:1103. doi:10.1056/nejmoa1904143
- JD Douketis et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022; 162:e207. doi:10.1016/j.chest.2022.07.025
- DR Holmes Jr et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015; 65:2614. doi:10.1016/j.jacc.2015.04.025
- P Osmancik et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 2020; 75:3122. doi:10.1016/j.jacc.2020.04.067
- P Kirchhof et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383:1305. doi:10.1056/nejmoa2019422
- A Rillig et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 2021; 144:845. doi:10.1161/circulationaha.121.05632
- D Kim et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ 2021; 373:n991. doi:10.1136/bmj.n991
- GA Upadhyay and FJ Alenghat. Catheter ablation for atrial fibrillation in 2019. JAMA 2019; 322:686. doi:10.1001/jama.2019.10929
- R Gopinathannair et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association. Circ Arrhythm Electrophysiol 2021; 14:e000078. doi:10.1161/hae.0000000000000078
- Safety of dronedarone (Multaq). Med Lett Drugs Ther 2011; 53:103.
- Crediblemeds. QTdrugs list. Available at: www.crediblemeds.org. Accessed December 18, 2023.
- JM Abraham et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772. doi:10.1161/circep.114.002339
- Q Lan et al. Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: a meta-analysis. Am J Emerg Med 2022; 51:248. doi:10.1016/j.ajem.2021.08.082
- LA Allen et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol 2015; 65:2691. doi:10.1016/j.jacc.2015.04.045
- D Kotecha et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020; 324:2497. doi:10.1001/jama.2020.23138
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
